 |
인쇄하기
취소
|
JW completes phase 3 study for biological response modifier
JW Pharmaceutical said Thursday it has completed its local Phase III study for Actemra (tocilizumab), an investigational biological therapy for rheumatoid arthritis.
According to the company, the local Phase III study of 100 subjects was conducted in several general hospitals from October 2009.
The results of this study demonstrated that Actemra reduced the signs and symptoms of rheumato...
According to the company, the local Phase III study of 100 subjects was conducted in several general hospitals from October 2009.
The results of this study demonstrated that Actemra reduced the signs and symptoms of rheumato...
Fees
- Email service daily and homepage access.
- $300 per month.
- 5 Email holders per each company.
- Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.